226
Views
0
CrossRef citations to date
0
Altmetric
Research Article

The Influence of Natural Pulmonary Surfactant on The Efficacy of siRNA-Loaded Dextran Nanogels

, , , &
Pages 1625-1638 | Received 18 Apr 2012, Published online: 30 Sep 2013

References

  • Raemdonck K , VandenbrouckeRE, DemeesterJ, SandersNN, De Smedt SC. Maintaining the silence: reflections on long-term RNAi. Drug Discov. Today13(21–22), 917–931 (2008).
  • Whitehead KA , LangerR, AndersonDG. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov.8(2), 129–138 (2009).
  • Kim DH , RossiJJ. Strategies for silencing human disease using RNA interference. Nat. Rev. Genet.8(3), 173–184 (2007).
  • Pecot CV , CalinGA, ColemanRL, Lopez-BeresteinG, SoodAK. RNA interference in the clinic: challenges and future directions. Nat. Rev. Cancer11(1), 59–67 (2011).
  • Davidson BL , MccrayPB Jr. Current prospects for RNA interference-based therapies. Nat. Rev. Genet.12(5), 329–340 (2011).
  • Lam JK , LiangW, ChanHK. Pulmonary delivery of therapeutic siRNA. Adv. Drug Deliv. Rev.64(1), 1–15 (2011).
  • Merkel OM , KisselT. Nonviral pulmonary delivery of siRNA. Acc. Chem. Res.45, 961–970 (2012).
  • Merkel OM , ZhengM, DebusH, KisselT. Pulmonary gene delivery using polymeric nonviral vectors. Bioconjug. Chem.23, 3–20 (2012).
  • Sanders N , RudolphC, BraeckmansK, De Smedt SC, Demeester J. Extracellular barriers in respiratory gene therapy. Adv. Drug Deliv. Rev.61(2), 115–127 (2009).
  • Weiss DJ . Delivery of gene transfer vectors to lung: obstacles and the role of adjunct techniques for airway administration. Mol. Ther.6(2), 148–152 (2002).
  • Blanco O , Perez-GilJ. Biochemical and pharmacological differences between preparations of exogenous natural surfactant used to treat respiratory distress syndrome: role of the different components in an efficient pulmonary surfactant. Eur. J. Pharmacol.568(1–3), 1–15 (2007).
  • Haagsman HP , HogenkampA, Van Eijk M, Veldhuizen EJ. Surfactant collectins and innate immunity. Neonatology93(4), 288–294 (2008).
  • Almlen A , StichtenothG, LinderholmBet al. Surfactant proteins B and C are both necessary for alveolar stability at end expiration in premature rabbits with respiratory distress syndrome. J. Appl. Physiol. 104(4), 1101–1108 (2008).
  • Duncan JE , WhitsettJA, HorowitzAD. Pulmonary surfactant inhibits cationic liposome-mediated gene delivery to respiratory epithelial cells in vitro. Hum. Gene Ther.8(4), 431–438 (1997).
  • Ernst N , UlrichskotterS, SchmalixWAet al. Interaction of liposomal and polycationic transfection complexes with pulmonary surfactant. J. Gene Med. 1(5), 331–340 (1999).
  • Rudolph C , LausierJ, NaundorfS, MullerRH, RoseneckerJ. In vivo gene delivery to the lung using polyethylenimine and fractured polyamidoamine dendrimers. J. Gene Med.2(4), 269–278 (2000).
  • Raemdonck K , NaeyeB, BuyensKet al. Biodegradable dextran nanogels for RNA interference: focusing on endosomal escape and intracellular siRNA delivery. Adv. Funct. Mater. 19(9), 1406–1415 (2009).
  • De Smedt SC , Van Thienen TG, Lucas B, Flesch FM, Van Nostrum CF, Demeester J. On the synthesis and characterization of biodegradable dextran nanogels with tunable degradation properties. Macromolecules38(20), 8503–8511 (2005).
  • Vandijkwolthuis WNE , TsangSKY, KettenesvandenboschJJ, HenninkWE. A new class of polymerizable dextrans with hydrolyzable groups: hydroxyethyl methacrylated dextran with and without oligolactate spacer. Polymer38(25), 6235–6242 (1997).
  • Zuo YY , VeldhuizenRA, NeumannAW, PetersenNO, PossmayerF. Current perspectives in pulmonary surfactant – inhibition, enhancement and evaluation. Biochim. Biophys. Acta1778(10), 1947–1977 (2008).
  • Zhang H , FanQ, WangYE, NealCR, ZuoYY. Comparative study of clinical pulmonary surfactants using atomic force microscopy. Biochim. Biophys. Acta1808(7), 1832–1842 (2011).
  • Lucas B , RemautK, BraeckmansK, HaustraeteJ, De Smedt SC, Demeester J. Studying pegylated DNA complexes by dual color fluorescence fluctuation spectroscopy. Macromolecules37(10), 3832–3840 (2004).
  • Buyens K , LucasB, RaemdonckKet al. A fast and sensitive method for measuring the integrity of siRNA–carrier complexes in full human serum. J. Control. Release 126(1), 67–76 (2008).
  • Payne CK , JonesSA, ChenC, ZhuangX. Internalization and trafficking of cell surface proteoglycans and proteoglycan-binding ligands. Traffic8(4), 389–401 (2007).
  • Carralot JP , KimTK, LenseigneBet al. Automated high-throughput siRNA transfection in raw 264.7 macrophages: a case study for optimization procedure. J. Biomol. Screen. 14(2), 151–160 (2009).
  • Tseng YC , MozumdarS, HuangL. Lipid-based systemic delivery of siRNA. Adv. Drug Deliv. Rev.61(9), 721–731 (2009).
  • Moschos SA , FrickM, TaylorBet al. Uptake, efficacy and systemic distribution of naked, inhaled siRNA and locked nucleic acid (LNA) antisense. Mol. Ther. 19(12), 2163–2168 (2011).
  • Caldorera-Moore M , GuimardN, ShiL, RoyK. Designer nanoparticles: incorporating size, shape and triggered release into nanoscale drug carriers. Expert Opin. Drug Deliv.7(4), 479–495 (2010).
  • Rejman J , OberleV, ZuhornIS, HoekstraD. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem. J.377(Pt 1), 159–169 (2004).
  • Steele TW , ZhaoX, TarchaP, KisselT. Factors influencing polycation/siRNA colloidal stability toward aerosol lung delivery. Eur. J. Pharm. Biopharm.80(1), 14–24 (2011).
  • Nguyen J , ReulR, BetzTet al. Nanocomposites of lung surfactant and biodegradable cationic nanoparticles improve transfection efficiency to lung cells. J. Control. Release 140(1), 47–54 (2009).
  • Benfer M , KisselT. Cellular uptake mechanism and knockdown activity of siRNA-loaded biodegradable DEAPA–PVA-g–PLGA nanoparticles. Eur. J. Pharm. Biopharm.80(2), 247–256 (2011).
  • Ruge CA , KirchJ, CanadasOet al. Uptake of nanoparticles by alveolar macrophages is triggered by surfactant protein A. Nanomedicine 7(6), 690–693 (2011).
  • Bates SR . P63 (CKAP4) as an SP-A receptor: implications for surfactant turnover. Cell. Physiol. Biochem.25(1), 41–54 (2010).
  • Griese M . Pulmonary surfactant in health and human lung diseases: state of the art. Eur. Respir. J.13(6), 1455–1476 (1999).
  • Frerking I , GuntherA, SeegerW, PisonU. Pulmonary surfactant: functions, abnormalities and therapeutic options. Intensive Care Med.27(11), 1699–1717 (2001).
  • Engle WA . Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics121(2), 419–432 (2008).
  • Maruscak A , LewisJF. Exogenous surfactant therapy for ARDS. Expert Opin. Investig. Drugs15(1), 47–58 (2006).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.